Alphabet posted $62.6B in Q1 net income as Google Cloud grew 63% and backlog swelled above $460B, sending Bay Area AI investments into overdrive.

A West Health–Gallup poll finds many Americans consult AI for health questions — and roughly 14 million say AI advice led them to skip care. Stanford’s chief data scientist weighs in.

PocketOS founder says a Cursor agent running Anthropic’s Claude wiped the company’s production database and volume backups in nine seconds; Railway says it restored the data.

Biogen beat Q1 estimates as Leqembi sales surged 74% to $168M, but the company trimmed full‑year EPS after booking deal‑related charges tied to the Apellis purchase.

Monthly DNA records from Station ALOHA show seasonal niche partitioning in more than 60% of ocean microbes, a pattern that persists down to deep sea and helps sustain food webs.

J. Craig Venter, the La Jolla genomics pioneer who helped map the human genome and later built synthetic cells, died April 29 at 79.

Charlotte‑based Truist awarded Infosys a more‑than‑$500M contract to build and run an offshore tech hub in India, a deal that could reshape where the bank’s tech work lives.

The Minnesota Senate voted unanimously to ban AI "nudification" tools that make nonconsensual nude images, creating civil remedies and steep penalties for operators. The bill now heads to the governor.

Texas Biomed researchers are developing a flu vaccine that could protect for years by targeting stable viral parts; animal studies are the next step.

JPMorgan is leaning on Tampa’s Highland Oaks teams to build AI and payments tools, reshaping hiring and boosting campus investment across the region.

Waukesha and La Crosse counties have put Aurelian’s Ava chatbot on non‑emergency 911 lines, handling thousands of routine calls while routing emergencies to human dispatchers.

DOJ's rescheduling of medical cannabis is opening investor pipelines for cannabis drug startups, prompting private raises and IPO talk while banks and state rules still complicate the picture.

Cambridge-based Axoft says it temporarily implanted its Fleuron brain probe in a Shanghai patient and closed a $55M Series A to expand trials and scale manufacturing.